Development of a lectin-Fc fusion protein with antiviral and anti-cancer activity.

HIV;biotechnology;drug development;lectin;antibody;plant-based protein expression

Matthew William Dent

University:University of Louisville

Department:Pharmacology and Toxicology

关键词: HIV;    biotechnology;    drug development;    lectin;    antibody;    plant-based protein expression;   

Others  :  https://ir.library.louisville.edu/cgi/viewcontent.cgi?article=4321&context=etd

美国|英语

来源: The Universite of Louisville's Institutional Repository

【 摘 要 】

This thesis describes the development of a novel lectin-Fc fusion protein and its antiviral and anti-cancer activity. The molecule, Avaren-Fc (AvFc), is a fusion of a variant of the actinomycete lectin actinohivin (Avaren) and the Fc region of human IgG1, and is selective for the terminal α1,2-mannose residues found at the ends of high-mannose-type glycans that can be found on the surface of certain heavily glycosylated viruses and cancer cells. Here, AvFc was found to be able to neutralize simian immunodeficiency virus as well as Hepatitis C virus with nanomolar IC50 values. Furthermore, AvFc recognizes a number of cell surface receptors and is capable of protecting mice against lung and flank B16F10 challenges primarily through Fc-mediated mechanisms. This work builds upon the framework developed by our group supporting the preclinical development of AvFc as a novel antiviral and anti-cancer protein.